ZIOPHARM is a biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment.
(Nasdaq:ZIOP)
Location: United States, Massachusetts, Boston
Investors 3
| Date | Name | Website |
| 14.05.2021 | EW Healthc... | ewhealthca... |
| - | Emerging T... | etpvc.com |
| - | Cycad Grou... | cycadvc.co... |
Mentions in press and media 16
| Date | Title | Description | Source |
| 26.02.2021 | NK cell therapy player Artiva makes some more noise, pul... | Not even one month after Big Pharma took notice of Artiva when Merck signed a collaboration... | endpts.com... |
| 26.02.2021 | Gossamer pushes ahead with failed asthma drug; Cullgen g... | After getting beaten up by investors over the key failure of its lead drug GB001, Gossamer had... | endpts.com... |
| 26.02.2021 | J&J adcomm live blog: Committee votes 22-0 to recom... | The US could have a third authorized Covid-19 vaccine within hours. The FDA’s advisory comm... | endpts.com... |
| 26.02.2021 | Perceptive's fourth — yes, fourth — SPAC jumps to Nasdaq ... | The biotech SPAC boom has gone almost hand-in-hand with the industry’s IPO gold rush, and this we... | endpts.com... |
| 26.02.2021 | Mark Mallon charts post-Ironwood course by taking CEO job... | Mark Mallon → Mark Mallon steps aside at Ironwood on March 12 after close to two years at the h... | endpts.com... |
| 26.02.2021 | The path to NASH: understanding the role of severe obes... | Biotech Voices is a collection of exclusive opinion editorials from some of the leading voices in bi... | endpts.com... |
| 26.02.2021 | Genentech plots $53M discovery quest aimed at sparking a... | New Roivant CEO Matt Gline has crafted an all-equity upfront deal to buy out a Boston-based biotech ... | endpts.com... |
| 25.02.2021 | Follow biotechs going public with the Endpoints News IPO... | Sarepta may be running into some trouble with its next-gen gene therapy approach to Duchenne muscula... | endpts.com... |
| 25.02.2021 | Follow biotechs going public with the Endpoints News IPO... | A couple weeks after racking up its third EUA for a Covid-19 treatment — this one for its antibody c... | endpts.com... |
| 25.02.2021 | Follow biotechs going public with the Endpoints News IPO... | Laurence Cooper has done his part. In the five years since he left a tenured position at Houston’s ... | endpts.com... |
Show more